Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Ironwood Pharmaceuticals Total Assets 2010-2024 | IRWD

Ironwood Pharmaceuticals total assets from 2010 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
  
Ironwood Pharmaceuticals Annual Total Assets
(Millions of US $)
2023 $471
2022 $1,101
2021 $1,127
2020 $559
2019 $403
2018 $332
2017 $606
2016 $710
2015 $619
2014 $329
2013 $279
2012 $230
2011 $209
2010 $301
2009 $162
Ironwood Pharmaceuticals Quarterly Total Assets
(Millions of US $)
2024-09-30 $390
2024-06-30 $396
2024-03-31 $439
2023-12-31 $471
2023-09-30 $524
2023-06-30 $603
2023-03-31 $1,155
2022-12-31 $1,101
2022-09-30 $1,040
2022-06-30 $976
2022-03-31 $1,083
2021-12-31 $1,127
2021-09-30 $1,079
2021-06-30 $1,007
2021-03-31 $599
2020-12-31 $559
2020-09-30 $492
2020-06-30 $444
2020-03-31 $404
2019-12-31 $403
2019-09-30 $334
2019-06-30 $316
2019-03-31 $364
2018-12-31 $332
2018-09-30 $417
2018-06-30 $618
2018-03-31 $571
2017-12-31 $606
2017-09-30 $625
2017-06-30 $705
2017-03-31 $701
2016-12-31 $710
2016-09-30 $732
2016-06-30 $700
2016-03-31 $603
2015-12-31 $619
2015-09-30 $613
2015-06-30 $654
2015-03-31 $306
2014-12-31 $329
2014-09-30 $346
2014-06-30 $371
2014-03-31 $419
2013-12-31 $279
2013-09-30 $326
2013-06-30 $384
2013-03-31 $325
2012-12-31 $230
2012-09-30 $247
2012-06-30 $209
2012-03-31 $249
2011-12-31 $209
2011-09-30 $219
2011-06-30 $250
2011-03-31 $272
2010-12-31 $301
2010-09-30 $305
2010-06-30 $322
2010-03-31 $338
2009-12-31 $162
2009-09-30 $150
2009-06-30 $0
2009-03-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.310B $0.443B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $78.557B 30.23
Chugai Pharmaceutical (CHGCY) Japan $73.258B 28.91
Takeda Pharmaceutical (TAK) Japan $43.305B 9.58
Sandoz Group AG (SDZNY) Switzerland $21.476B 0.00
Merck (MKKGY) Germany $19.083B 17.09
Astellas Pharma (ALPMY) Japan $16.957B 12.01
United Therapeutics (UTHR) United States $15.793B 15.54
Summit Therapeutics (SMMT) United States $15.243B 0.00
Neurocrine Biosciences (NBIX) United States $15.239B 45.75
Shionogi (SGIOY) Japan $12.318B 12.34
Orion OYJ (ORINY) Finland $7.466B 20.99
Madrigal Pharmaceuticals (MDGL) United States $7.203B 0.00
Corcept Therapeutics (CORT) United States $7.129B 54.00
Stevanato Group S.p.A (STVN) Italy $6.808B 44.08
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.911B 0.00
Ionis Pharmaceuticals (IONS) United States $5.152B 0.00
Grifols, S.A (GRFS) Spain $4.806B 0.00
Ono Pharmaceutical (OPHLF) Japan $4.779B 9.78
Crinetics Pharmaceuticals (CRNX) United States $3.590B 0.00
Recursion Pharmaceuticals (RXRX) United States $2.829B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.750B 12.47
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.469B 14.76
Centessa Pharmaceuticals (CNTA) United Kingdom $2.352B 0.00
Soleno Therapeutics (SLNO) United States $2.198B 0.00
Hypermarcas (HYPMY) Brazil $2.068B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $1.949B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.808B 0.00
Dyne Therapeutics (DYN) United States $1.706B 0.00
Evotec AG (EVO) Germany $1.666B 0.00
Indivior (INDV) United States $1.468B 5.98
Guardian Pharmacy Services (GRDN) United States $1.408B 0.00
Ardelyx (ARDX) United States $1.343B 0.00
ARS Pharmaceuticals (SPRY) United States $1.244B 0.00
Xencor (XNCR) United States $1.207B 0.00
Ocular Therapeutix (OCUL) United States $1.201B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.158B 0.00
Harrow (HROW) United States $1.105B 0.00
Enliven Therapeutics (ELVN) United States $1.098B 0.00
Collegium Pharmaceutical (COLL) United States $0.998B 5.45
Bioventus (BVS) United States $0.880B 27.80
Cronos Group (CRON) Canada $0.773B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.771B 0.00
Relay Therapeutics (RLAY) United States $0.755B 0.00
Verve Therapeutics (VERV) United States $0.708B 0.00
USANA Health Sciences (USNA) United States $0.595B 11.03
Elite Pharmaceuticals (ELTP) United States $0.556B 0.00
Xeris Biopharma Holdings (XERS) United States $0.540B 0.00
OmniAb (OABI) United States $0.524B 0.00
Altimmune (ALT) United States $0.491B 0.00
Savara (SVRA) United States $0.487B 0.00
ProKidney (PROK) United States $0.484B 0.00
KalVista Pharmaceuticals (KALV) United States $0.475B 0.00
Akebia Therapeutics (AKBA) United States $0.471B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.468B 0.00
Oruka Therapeutics (ORKA) United States $0.458B 0.00
Organogenesis (ORGO) United States $0.446B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.430B 174.21
Zevra Therapeutics (ZVRA) United States $0.421B 0.00
Siga Technologies (SIGA) United States $0.413B 4.82
Tourmaline Bio (TRML) United States $0.384B 0.00
Esperion Therapeutics (ESPR) United States $0.365B 0.00
Aldeyra Therapeutics (ALDX) United States $0.357B 0.00
Korro Bio (KRRO) United States $0.339B 0.00
4D Molecular Therapeutics (FDMT) United States $0.301B 0.00
CytoDyn (CYDY) United States $0.277B 0.00
Aquestive Therapeutics (AQST) United States $0.275B 0.00
Heron Therapeutics (HRTX) United States $0.272B 0.00
Nature's Sunshine Products (NATR) United States $0.271B 16.10
Amylyx Pharmaceuticals (AMLX) United States $0.257B 0.00
Innate Pharma SA (IPHYF) France $0.243B 0.00
Avita Medical (RCEL) United States $0.240B 0.00
Larimar Therapeutics (LRMR) United States $0.229B 0.00
MediWound (MDWD) Israel $0.210B 0.00
Acrivon Therapeutics (ACRV) United States $0.203B 0.00
Profound Medical (PROF) Canada $0.184B 0.00
Lexeo Therapeutics (LXEO) United States $0.179B 0.00
Aclaris Therapeutics (ACRS) United States $0.174B 0.00
Lyell Immunopharma (LYEL) United States $0.173B 0.00
Silence Therapeutics (SLN) United Kingdom $0.172B 0.00
Inhibikase Therapeutics (IKT) United States $0.169B 0.00
VAXART, INC (VXRT) United States $0.168B 0.00
Nanobiotix S.A (NBTX) France $0.166B 0.00
Champions Oncology (CSBR) United States $0.147B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.138B 0.00
Telomir Pharmaceuticals (TELO) United States $0.135B 0.00
Nektar Therapeutics (NKTR) United States $0.129B 0.00
Cardiol Therapeutics (CRDL) Canada $0.120B 0.00
Cassava Sciences (SAVA) United States $0.113B 0.00
Achieve Life Sciences (ACHV) Canada $0.110B 0.00
ElectroCore (ECOR) United States $0.106B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.106B 0.00
Journey Medical (DERM) United States $0.104B 0.00
Inotiv (NOTV) United States $0.102B 0.00
Protara Therapeutics (TARA) United States $0.100B 0.00
Metagenomi (MGX) United States $0.099B 0.00
Pyxis Oncology (PYXS) United States $0.087B 0.00
Arch Biopartners (ACHFF) Canada $0.086B 0.00
Avalo Therapeutics (AVTX) United States $0.085B 0.00
Regulus Therapeutics (RGLS) United States $0.083B 0.00
Karyopharm Therapeutics (KPTI) United States $0.083B 0.00
Galectin Therapeutics (GALT) United States $0.083B 0.00
Fractyl Health (GUTS) United States $0.077B 0.00
Assertio Holdings (ASRT) United States $0.077B 20.20
ESSA Pharma (EPIX) Canada $0.075B 0.00
Mural Oncology (MURA) Ireland $0.075B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.075B 0.00
Nutriband (NTRB) United States $0.074B 0.00
PMV Pharmaceuticals (PMVP) United States $0.074B 0.00
Gain Therapeutics (GANX) United States $0.070B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.069B 0.00
Vivani Medical (VANI) United States $0.069B 0.00
Context Therapeutics (CNTX) United States $0.067B 0.00
Century Therapeutics (IPSC) United States $0.065B 0.00
Unicycive Therapeutics (UNCY) United States $0.063B 0.00
Prelude Therapeutics (PRLD) United States $0.061B 0.00
AleAnna (ANNA) United States $0.061B 0.00
OptiNose (OPTN) United States $0.060B 0.00
FibroGen (FGEN) United States $0.050B 0.00
AlloVir (ALVR) United States $0.050B 0.00
NRx Pharmaceuticals (NRXP) United States $0.050B 0.00
Rafael Holdings (RFL) United States $0.049B 0.00
SCYNEXIS (SCYX) United States $0.044B 0.00
CASI Pharmaceuticals (CASI) China $0.042B 0.00
Iterum Therapeutics (ITRM) Ireland $0.041B 0.00
Tempest Therapeutics (TPST) United States $0.040B 0.00
Incannex Healthcare (IXHL) Australia $0.039B 0.00
Surrozen (SRZN) United States $0.036B 0.00
VYNE Therapeutics (VYNE) United States $0.036B 0.00
BioVie (BIVI) United States $0.035B 0.00
Jupiter Neurosciences (JUNS) United States $0.034B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.031B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.030B 0.00
Traws Pharma (TRAW) United States $0.030B 0.00
PolyPid (PYPD) Israel $0.030B 0.00
Scienture Holdings (SCNX) United States $0.029B 0.00
Natural Alternatives (NAII) United States $0.026B 0.00
DURECT (DRRX) United States $0.024B 0.00
Vivos Therapeutics (VVOS) United States $0.024B 0.00
Citius Pharmaceuticals (CTXR) United States $0.023B 0.00
Enlivex Therapeutics (ENLV) Israel $0.022B 0.00
Mannatech (MTEX) United States $0.022B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.021B 0.00
Carisma Therapeutics (CARM) United States $0.021B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.021B 0.00
Lipocine (LPCN) United States $0.020B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.019B 0.00
MEI Pharma (MEIP) United States $0.019B 0.00
Dominari Holdings (DOMH) United States $0.018B 0.00
GlycoMimetics (GLYC) United States $0.018B 0.00
Cosmos Health (COSM) United States $0.017B 0.00
Minerva Neurosciences (NERV) United States $0.017B 0.00
Phio Pharmaceuticals (PHIO) United States $0.014B 0.00
Lyra Therapeutics (LYRA) United States $0.012B 0.00
Talphera (TLPH) United States $0.012B 0.00
TherapeuticsMD (TXMD) United States $0.012B 0.00
Nuvilex (PMCB) United States $0.011B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.011B 0.00
Relmada Therapeutics (RLMD) United States $0.010B 0.00
Jaguar Animal Health (JAGX) United States $0.010B 0.00
Biomerica (BMRA) United States $0.010B 0.00
Klotho Neurosciences (KLTO) United States $0.010B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.009B 0.00
Mangoceuticals (MGRX) United States $0.009B 0.00
Ainos (AIMD) United States $0.008B 0.00
Addex Therapeutics (ADXN) Switzerland $0.008B 0.00
Indaptus Therapeutics (INDP) United States $0.008B 0.00
TransCode Therapeutics (RNAZ) United States $0.008B 0.00
Plus Therapeutics (PSTV) United States $0.008B 0.00
Redhill Biopharma (RDHL) Israel $0.007B 0.00
BioLineRx (BLRX) Israel $0.007B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.007B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Aptorum Group (APM) United Kingdom $0.006B 0.00
ProPhase Labs (PRPH) United States $0.006B 0.00
Clearmind Medicine (CMND) Canada $0.006B 0.00
SciSparc (SPRC) Israel $0.005B 0.00
Bio-Path Holdings (BPTH) United States $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.003B 0.00
CERo Therapeutics Holdings (CERO) United States $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
Petros Pharmaceuticals (PTPI) United States $0.003B 0.00
Avenue Therapeutics (ATXI) United States $0.003B 0.07
SHINECO (SISI) China $0.003B 0.00
Alaunos Therapeutics (TCRT) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.002B 0.00
InMed Pharmaceuticals (INM) Canada $0.002B 0.00
Heatwurx (PCSA) United States $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.002B 0.00
China SXT Pharmaceuticals (SXTC) China $0.002B 0.00
Conduit Pharmaceuticals (CDT) United States $0.002B 0.00
Aditxt (ADTX) United States $0.001B 0.00
PainReform (PRFX) Israel $0.000B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00